Human Recombinant IGFBP-4

Insulin-like growth factor-binding protein 4 (IGFBP-4) inhibits the actions of IGF-I and IGF-II. The distribution of IGFBP-4 in tissues is dependent on its glycosylation state, however it preferentially targets connective tissue (Firth and Baxter; Qin et al.). IGFBP-4 is also produced in liver, adrenal glands, Leydig cells, developing embryos, spinal cord, and thymic cortex. IGFBP-4 inhibits WNT/β-catenin signaling, which downregulates prostate cancer proliferation (Zhu et al.). In vitro studies suggest that IGFBP-4 inhibits proliferation of neuroblastoma and glioma, while promoting bone loss in osteosarcoma and multiple myeloma (Durai et al.).

Caution: Product restrictions: (i) Customer shall not make products or any portion of them in any way, shape or form, including as a component of another product available for the purpose of further resale or alter or remove the Product label and the Supplier’s mark of origin without express written permission of Supplier and (ii) Customer is familiar with Supplier’s restrictions on the use of the products and shall use the products in compliance with such restrictions and the applicable Supplier Product Information sheet (collectively, the 'Product Restrictions').